Clinical Trials Logo

Clinical Trial Summary

People suffering from diabetes often have high blood sugar levels. Over time this can affect many organs including the nerves in hands and feet and can cause a nerve pain called diabetic neuropathic pain (DNP). There are treatments for DNP but in many patients they do not reach a good pain reduction and have unwanted side effects. In this trial, the researchers will look at how BAY1817080 works and how safe it is. They will compare it to a placebo or another treatment for DNP called pregabalin. A placebo looks like a treatment but does not have any medicine in it. The researchers will use a placebo to learn if the participants' results are due to BAY1817080 or if the results could be due to chance. The researchers will also learn more about the right dose of BAY1817080 for these participants. The trial will include participants who have DNP and either type 1 or type 2 diabetes. It will include about 440 men and women who are at least 18 years old. This trial will have 2 parts. In Part 1, the participants will take either BAY1817080 or the placebo. These treatments will be taken as a tablet by mouth twice a day for 8 weeks. In Part 2, participants will take BAY 1817080, pregabalin, or a matching placebo of either treatment. BAY1817080 and a placebo will be taken as a tablet by mouth twice a day for 12 weeks. Pregabalin and a placebo will be taken as a capsule by mouth twice a day for 12 weeks. The participants in Part 1 will visit their trial site 6 times. The participants in Part 2 will visit their trial site 7 times. At these visits, the doctors will ask the participants if they have any health problems, take blood samples, and do a physical exam. They will also ask the participants to complete questionnaires about their pain and other symptoms.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Neuralgia
  • Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
  • Peripheral Nervous System Diseases

NCT number NCT04641273
Study type Interventional
Source Bayer
Contact
Status Terminated
Phase Phase 2
Start date January 22, 2021
Completion date October 18, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06383702 - Phase III Trial to Evaluate the Efficacy and Safety of Pregabalin in the Treatment of Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT05219812 - A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain Phase 2